A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study
暂无分享,去创建一个
Ibrahim M. Ibrahim | I. Eissa | A. Metwaly | Dalal Z. Husein | H. Elkady | E. Elkaeed | Reda G. Yousef | B. A. Alsfouk | Aisha A. Alsfouk
[1] Ibrahim M. Ibrahim,et al. A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro Studies , 2022, Processes.
[2] Divya Vemula,et al. CADD, AI and ML in Drug Discovery: A Comprehensive Review. , 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] Ibrahim M. Ibrahim,et al. New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies , 2022, Molecules.
[4] I. Eissa,et al. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease , 2022, International journal of molecular sciences.
[5] M. M. Khalifa,et al. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation , 2022, Journal of enzyme inhibition and medicinal chemistry.
[6] E. S. Nossier,et al. Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers , 2022, Journal of enzyme inhibition and medicinal chemistry.
[7] Wagdy M. Eldehna,et al. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies , 2022, Journal of enzyme inhibition and medicinal chemistry.
[8] Ibrahim M. Ibrahim,et al. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects , 2022, Molecules.
[9] S. M. Abou-Seri,et al. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease , 2022, International journal of molecular sciences.
[10] Tongtong Wang,et al. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: disposing of waste with waste , 2022, Environmental Science and Pollution Research.
[11] Sun Choi,et al. Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD) , 2022, Biochemical Society transactions.
[12] A. Muthuraman,et al. Computer-Aided Drug Discovery (CADD) Approaches for the Management of Neuropathic Pain. , 2021, Current topics in medicinal chemistry.
[13] A. A. Eissa,et al. Design and synthesis of novel furan, furo[2,3-d]pyrimidine and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential VEGFR-2 inhibitors. , 2021, Bioorganic chemistry.
[14] S. Wakode,et al. Logical synthetic strategies and structure-activity relationship of indolin-2-one hybrids as small molecule anticancer agents: An Overview , 2021, Journal of Molecular Structure.
[15] R. Hassanien,et al. Cadmium oxide nanoparticles/graphene composite: synthesis, theoretical insights into reactivity and adsorption study , 2021, RSC advances.
[16] Amr M Hilal Abdou,et al. Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. , 2021, Bioorganic chemistry.
[17] D. Dou,et al. Traditional ancient Egyptian medicine: A review , 2021, Saudi journal of biological sciences.
[18] H. Luesch,et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M. , 2020, Organic & biomolecular chemistry.
[19] Linlin Zhao,et al. Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling. , 2020, Drug discovery today.
[20] A. Foroumadi,et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. , 2020, Bioorganic chemistry.
[21] Erlotinib , 2020, Reactions Weekly.
[22] K. Sasikala,et al. Molecular Docking in Modern Drug Discovery: Principles and Recent Applications , 2019, Drug Discovery and Development - New Advances.
[23] S. Pandey,et al. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer’s Agents , 2020, Current computer-aided drug design.
[24] Pedro H M Torres,et al. Key Topics in Molecular Docking for Drug Design , 2019, International journal of molecular sciences.
[25] K. Saied,et al. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. , 2019, Bioorganic chemistry.
[26] Le Zhang,et al. Progress in molecular docking , 2019, Quantitative Biology.
[27] A. Metwaly,et al. Black Ginseng and Its Saponins: Preparation, Phytochemistry and Pharmacological Effects , 2019, Molecules.
[28] Adriano D Andricopulo,et al. ADMET modeling approaches in drug discovery. , 2019, Drug discovery today.
[29] Chaoyang Zhang,et al. A review on machine learning methods for in silico toxicity prediction , 2018, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[30] V. Gandin,et al. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily , 2015, Scientific Reports.
[31] Xiao Dong Xu,et al. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance , 2015, Chinese journal of cancer.
[32] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[33] S. Zappavigna,et al. Erlotinib: early clinical development in brain cancer , 2014, Expert opinion on investigational drugs.
[34] Jing Wu,et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. , 2014, Molecular and clinical oncology.
[35] S. Ou. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. , 2012, Critical reviews in oncology/hematology.
[36] K. Dittmann,et al. EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[37] R D Benz,et al. (Q)SAR Modeling and Safety Assessment in Regulatory Review , 2012, Clinical pharmacology and therapeutics.
[38] Peter Ballard,et al. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[39] K. Berg,et al. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. , 2007, Molecular pharmaceutics.
[40] Ulf Norinder,et al. Prediction of ADMET Properties , 2006, ChemMedChem.
[41] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.
[42] N. Normanno,et al. Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.
[43] P. Zimmerman,et al. Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen , 2005, Clinical Cancer Research.
[44] R. Pazdur,et al. FDA drug approval summary: erlotinib (Tarceva) tablets. , 2005, The oncologist.
[45] F. Penault-Llorca,et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] Maria Kontoyianni,et al. Evaluation of docking performance: comparative data on docking algorithms. , 2004, Journal of medicinal chemistry.
[47] P. Bonomi. Erlotinib: a new therapeutic approach for non-small cell lung cancer , 2003, Expert opinion on investigational drugs.
[48] John C. Dearden,et al. In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..
[49] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[50] P. Furet,et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. , 1997, Journal of medicinal chemistry.
[51] Pascal Furet,et al. Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411 , 1995, J. Comput. Aided Mol. Des..